Jefferies Financial Group Inc. Trims Stake in Charles River Laboratories International, Inc. $CRL

Jefferies Financial Group Inc. reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 34.8% in the second quarter, Holdings Channel.com reports. The institutional investor owned 8,872 shares of the medical research company’s stock after selling 4,742 shares during the period. Jefferies Financial Group Inc.’s holdings in Charles River Laboratories International were worth $1,346,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Brooklyn Investment Group grew its holdings in shares of Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after acquiring an additional 86 shares during the period. Cromwell Holdings LLC boosted its position in shares of Charles River Laboratories International by 542.9% during the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 152 shares in the last quarter. Neo Ivy Capital Management purchased a new stake in Charles River Laboratories International in the second quarter worth $29,000. Allworth Financial LP raised its holdings in Charles River Laboratories International by 172.7% in the second quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock worth $45,000 after purchasing an additional 190 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new position in Charles River Laboratories International in the second quarter worth $56,000. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Trading Up 0.4%

Shares of NYSE CRL opened at $178.76 on Thursday. The firm’s 50 day moving average price is $170.79 and its 200-day moving average price is $159.67. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $203.01. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. The company has a market cap of $8.80 billion, a PE ratio of -134.41, a P/E/G ratio of 4.83 and a beta of 1.53.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.11. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $990.43 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The firm’s quarterly revenue was down .5% compared to the same quarter last year. During the same quarter last year, the firm earned $2.59 earnings per share. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CRL. Baird R W upgraded shares of Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 6th. Argus set a $200.00 price objective on shares of Charles River Laboratories International in a research note on Monday, November 17th. Morgan Stanley raised their target price on shares of Charles River Laboratories International from $170.00 to $185.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 11th. Mizuho boosted their price target on Charles River Laboratories International from $155.00 to $174.00 and gave the stock a “neutral” rating in a research report on Friday, October 17th. Finally, Wall Street Zen downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $190.86.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).